The new initiative aims to improve early detection by increasing access to screening in communities where accessing care is more difficult.

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

DelveInsight's "VITRAKVI Market Size, Forecast, and Market Insight Report" highlights the details around VITRAKVI, a TRK, ...

VITRAKVI has strong market potential as a first-in-class TRK inhibitor for patients with NTRK gene fusion-positive cancers, regardless of tumor type. The growing adoption of precision oncology ...